Clinical Trials Logo

Triple Negative Breast Neoplasms clinical trials

View clinical trials related to Triple Negative Breast Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06057636 Withdrawn - Breast Cancer Clinical Trials

Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study

Start date: September 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two hypnotic interventions for Black women with advanced cancer pain in preparation for a well-powered phase III study. The investigators plan to enroll 30 adult Black women with advanced cancer pain in a 2-arm pilot randomized controlled trial (RCT). The primary aim will be to evaluate the feasibility of conducting the 2-arm clinical trial. It is hypothesized that at least 75% of participants in both study arms will complete study requirements. The secondary aims will be to evaluate the participant's experience with the intervention and to determine the effect size of the intervention on pain severity.

NCT ID: NCT05809895 Withdrawn - Clinical trials for Triple Negative Breast Cancer

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

AdvanTIG-211
Start date: September 15, 2023
Phase: Phase 2
Study type: Interventional

The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and chemotherapy as first-line therapy for adult men and women with advanced triple negative breast cancer (TNBC) whose tumors express programmed death ligand 1 (PD - L1) [combined positive score (CPS) ≥10], regardless of study treatment discontinuation or start of new anti-neoplastic therapy.

NCT ID: NCT05774886 Withdrawn - Breast Cancer Clinical Trials

Implantable Microdevice for TNBC - Pilot Study

Start date: May 2023
Phase: Phase 1
Study type: Interventional

The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the effectiveness of several cancer drugs against early stage Triple Negative Breast Cancer (TNBC). The name of the intervention involved in this study is: Implantable Microdevice (IMD)

NCT ID: NCT05255666 Withdrawn - Clinical trials for Triple Negative Breast Cancer

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Start date: July 31, 2023
Phase: Phase 2
Study type: Interventional

The study is a phase II with safety lead in, single arm, study using Nal-IRI in combination with pembrolizumab. Nal-IRI will be given IV every 2 weeks starting at 50mg/m2. Pembrolizumab will be given 400mg IV every 6 weeks. Treatment will continue until progression, intolerable side effects or patient/doctor decision to discontinue treatment.

NCT ID: NCT05234606 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Start date: March 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4 expression.

NCT ID: NCT05233696 Withdrawn - Clinical trials for Metastatic Breast Cancer

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Start date: January 4, 2022
Phase: Phase 2
Study type: Interventional

Patients with locally advanced unresectable or metastatic programmed cell death ligand (PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to one-four sites of metastasis amenable to radiation (sites of disease to be selected at the discretion of the treating radiation oncologist) followed by initiation of systemic therapy with pembrolizumab plus nab-paclitaxel/paclitaxel. Patients will be treated with pembrolizumab plus nab-paclitaxel/paclitaxel within 7 days of completion of radiation. Repeat imaging of all sites of disease will be performed every 9 weeks and response will be assessed according to RECIST 1.1.

NCT ID: NCT05209529 Withdrawn - BRCA1 Mutation Clinical Trials

Chemo-free BRCA-targeted Neoadjuvant Strategy

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter randomized phase ll clinical trial to evaluate the pathological complete response (pCR) in the tumour burden (primary and lymph nodes) with olaparib alone or in the olaparib and durvalumab arm in TNBC patients candidate for neoadjuvant strategy showing a t/gBRCAmut or BRCAness/HRD profile.

NCT ID: NCT05062174 Withdrawn - BRCA1 Mutation Clinical Trials

Breast Cancer BRCA1 Carriers: a Pilot Study

Start date: November 1, 2021
Phase:
Study type: Observational

The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates may lead to breast cancer) mutations undergoing a planned prophylactic mastectomy (having one or both breasts removed).

NCT ID: NCT05008510 Withdrawn - Clinical trials for Metastatic Triple Negative Breast Cancer

P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .

VERU-111
Start date: December 30, 2021
Phase: Phase 2
Study type: Interventional

To compare the following: 1. The efficacy of sabizabulin monotherapy to sacituzumab govitecan-hziy monotherapy 2. The efficacy of sacituzumab govitecan-hziy/sabizabulin combination therapy to sacituzumab govitecan-hziy monotherapy These comparisons will be made in the efficacy in the treatment of metastatic triple negative breast cancer (mTNBC) in patients previously treated with at least two systemic chemotherapies for metastatic disease as measured by radiographic progression free survival (rPFS) as the primary endpoint.

NCT ID: NCT04602117 Withdrawn - Ovarian Cancer Clinical Trials

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.